Flow sensing vascular implant
By embedding sensors in the vascular stent to monitor blood flow resistance and pressure changes in real time, the problem of difficult detection of stenosis recurrence in the prior art is solved, real-time monitoring and early warning of blood flow in the stent is achieved, and the risk of treatment is reduced and cost.
Patent Information
- Application Number
- CN202380031285.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-31
- Filing Date
- 2023-03-20
- Publication Date
- 2024-11-15
AI Technical Summary
The existing vascular stent monitoring technology lacks location specificity and early detection capabilities, resulting in timely detection of relapses of stenosis, increasing the risk of surgery and treatment costs.
Embed sensors in the vascular stent to monitor blood flow conditions at the stent in real time by measuring changes in blood flow resistance and pressure, and generate a curve of blood flow resistance to time to evaluate and warn of the occurrence of stenosis.
Real-time non-invasive monitoring of blood flow in the stent is achieved, location-specific information is provided, early detection of stenosis, reduce the need for imaging examinations, and reduce patient risks and treatment costs.
Smart Images

Figure CN118973467A_ABST
Abstract
Description
Technical Field
[0001] The following generally relates to the art of vascular stents, the art of blood flow sensing, the art of pressure sensing, the art of temperature sensing, the art of stenosis sensing, and related arts. Background Art
[0002] The onset of vascular disease (including arterial disease and vascular disease) often becomes a chronic condition that lasts a lifetime and requires ongoing monitoring. Recurrence of disease manifestations (e.g., plaque accumulation leading to narrowing of the vessel lumen, known as stenosis) is common, often resulting in additional invasive treatment. Early detection of recurrent stenosis is critical to minimizing the severity of any medical intervention, both reducing surgical risk for the patient and preserving future treatment options. Current monitoring and detection techniques (including symptom observation, external ultrasound, and intravascular fluoroscopy) have multiple limitations, including lack of location specificity, anatomical access restrictions, surgical risk, and cost.
[0003] A common treatment for patients with stenosis is to receive a stent to restore adequate blood flow through the narrowed area of the vessel affected by the disease. Restenosis after stenting is a common phenomenon due to the accumulation of plaque or other clotting materials inside the stent in the presence of underlying biological conditions and lifestyle-induced diseases. In fact, the nature of the stent as a foreign (and sometimes non-biological) material in the body increases the likelihood of stenosis accumulation at the stent.
[0004] Restenosis is often detected by the recurrence of patient-reported symptoms (pain, swelling, discoloration). This form of detection is not only untimely, as it requires significant disease progression to trigger symptom development, but it also provides little information about the location of the disease. Symptoms may be caused by restenosis in a previously treated portion of the vessel, or by the onset of stenosis in a previously healthy portion of the vessel.
[0005] Ankle-brachial blood pressure comparison or tissue oxygenation measurement are other non-invasive, scalable detection techniques. However, they also lack specific information about the location of the disease. For example, the ankle-brachial blood pressure comparison can only indicate the presence of at least one stenotic area somewhere between the ankle-brachial blood pressure measurement locations.
[0006] Other detection modalities such as external ultrasound (US) or intravascular fluoroscopy are able to detect restenosis before symptom onset and provide location specificity, but cost, surgical risks, and limited anatomical access (i.e., external US is ineffective for detecting stenoses in the pelvic vasculature, for example) make these techniques unsuitable for frontline detection.
[0007] Certain improvements that overcome these and other problems are disclosed below. Summary of the invention
[0008] In some embodiments disclosed herein, a vascular treatment device includes a stent and at least one sensor, wherein the stent includes a tube having an inner surface defining a central lumen, the stent being configured to be placed at a treatment site in a blood vessel of an associated patient, and the at least one sensor being attached to or embedded in the inner surface of the stent.
[0009] In some embodiments disclosed herein, a vascular treatment device includes a stent and at least one pressure sensor, wherein the stent includes a tube having an inner surface defining a central lumen, the stent is configured to be placed at a treatment site in a blood vessel of an associated patient, the at least one pressure sensor is attached to or embedded in the inner surface of the stent, and the at least one pressure sensor is configured to collect at least one pressure measurement result including blood flow resistance.
[0010] In some embodiments disclosed herein, a vascular treatment method includes: receiving a measurement result of blood flow resistance caused by a stent installed in a blood vessel, the blood flow resistance measurement result being based on at least one measurement performed using one or more sensors; repeating the blood flow resistance measurement in successive time periods to generate a curve of blood flow resistance relative to time; evaluating restenosis at the stent based on the curve of blood flow resistance relative to time; and outputting an indication of the evaluation of restenosis on a display device.
[0011] One advantage resides in providing real-time, non-invasive monitoring of blood flow through a previously implanted stent.
[0012] Another advantage resides in early detection of disease progression and providing the treating physician with site-specific information critical in planning additional treatment.
[0013] Another advantage resides in monitoring and preventing restenosis at a stent implanted in a patient.
[0014] Another advantage resides in reducing the need to image potential restenosis in a patient.
[0015] A given embodiment may provide none, one, two, more, or all of the foregoing advantages, and / or may provide other advantages that will become apparent to one of ordinary skill in the art upon reading and understanding the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The present disclosure may take the form of various components and arrangements of components, and in various steps and arrangements of steps.The drawings are only for the purpose of illustrating the preferred embodiments and are not to be construed as limiting the present disclosure.
[0017] Figure 1 A vascular treatment device according to the present disclosure is schematically illustrated.
[0018] Figure 2 and Figure 3 Shows Figure 1 Other embodiments of the device.
[0019] Figure 4 Schematic diagram of the use Figure 1 A method of performing a vascular treatment method using a device. DETAILED DESCRIPTION
[0020] One concern with stents is that restenosis can occur at the stent site. Typically, this is monitored by techniques such as Doppler ultrasound imaging. However, the stent interferes with ultrasound image quality, and it is challenging to detect material buildup on the stent by external imaging. Intravascular ultrasound imaging can provide higher image quality, but at the expense of subsequent invasive endovascular procedures for the patient.
[0021] An alternative approach is disclosed below, in which a sensor is embedded in the stent and remains in the patient with the stent to provide monitoring for any restenosis.
[0022] In one contemplated embodiment, a passive pressure sensor is used. Such a sensor can advantageously be highly miniaturized (e.g., in micrometers in size) and passive (because it uses an externally applied magnetic field for power and operation). In one specific embodiment, two such sensors are placed at the upstream and downstream ends of the stent, respectively. The pressure difference between the two sensors provides a measure of the flow resistance presented by the stent. In one method, the sensor reading is collected immediately after the stent is placed, and the sensor reading is collected in a subsequent time curve (e.g., during a follow-up doctor's office visit). Then restenosis will appear as a gradually increasing flow resistance over time. In some examples, when multiple stents are placed inside a blood vessel, the pressure gradient between the stents can be determined. In other examples, pressure measurements can be measured at the site of the stent, and pressure measurements can be made at different sites using a cuff, and the resulting pressure difference can be measured to determine stenosis. In another example, external Doppler ultrasound blood flow (Q) can be measured in conjunction with the pressure gradient (ΔP) measurement at the stent. The actual resistance R can be calculated as R=ΔP / Q.
[0023] This type of sensor can detect restenosis in another way, that is, when biological material overgrows and accumulates on the inner wall of the stent and the pressure sensor, this overgrowth exerts a force (corresponding to pressure) on the sensor. An increase in the measured "pressure" corresponds to an increase in restenosis. One suitable method is to measure the sensor readings of various clinical research subjects to determine how the trend line of the pressure readings (or pressure difference readings (in the embodiment of two sensors)) over time corresponds to significant restenosis.
[0024] In order to be able to measure the blood pressure in the stent lumen (or to detect restenosis by the forces exerted by the overgrowth of biological material), a pressure sensor is appropriately placed inside the stent (i.e., on the wall of the stent lumen). It should be noted that pressure or flow measurements as used herein do not necessarily mean measurements expressed in standard pressure or flow units, but more generally encompass pressure and / or flow related metrics measured by (one or more) sensors provided with the stent.
[0025] Although completely passive sensors are advantageous, it is also conceivable to use one or more active flow sensors in the support. For example, it is conceivable to use a sensor that includes a storage capacitor for inductively powering the sensor for measurement.
[0026] In another approach, the embedded sensor can be a temperature sensor, and a cooled saline or contrast solution can be injected into the patient (or other subject), and then the uptake of the cooled saline fluid by the vessel containing the stent is detected by the temperature shift measured by the embedded temperature sensor. Here, the delayed uptake is expected to correspond to an increase in the flow resistance of the stent, and therefore to restenosis. In another example, the patient can breathe (cold) air, and the phase delay between the first "warm" temperature blood measurement and the second "cold" temperature blood measurement can be analyzed.
[0027] If the sensor is radiopaque (or has a radiopaque coating), it can also be used as a marker for locating the stent in imaging during stent placement.By replacing conventional fluoroscopic markers thereby, the number of parts of the stent is not increased.
[0028] The disclosed methods are applicable to use with any type of stent, including but not limited to self-expanding nitinol stents.
[0029] Stent and other vascular implants can also be combined with lugs or rings or other geometric expansions in their structures to provide improved visibility when observed under fluoroscopy. A different embodiment envisions replacing these features completely or in part with sensing elements. An element placed at either end, both ends or along its length of an implant can measure a physiologically significant parameter (e.g., pressure) at a specific location in the region of the implant. Then, the change of this parameter can be used to detect the early onset of disease progression (e.g., blood flow changes indicate restenosis). Additionaly or alternatively, a sensor providing position information can be included in the stent and used to detect compression, expansion or fracture / failure of implanted stents. A sensor placed inside the stent (e.g., a sensor attached to or embedded in the inner surface of the stent) is suitably aligned with blood, thereby suitably aligned with the blood-stent interface. This helps to measure tissue overgrowth and predict patency loss on the inner surface of the stent, and even intervenes earlier to improve stent patency.
[0030] refer to Figure 1 , schematically illustrates an exemplary vascular treatment (i.e., thrombectomy or atherectomy) device 1. Figure 1 As shown, apparatus 1 includes a treatment device 10, which includes a vascular treatment device 2 (e.g., a self-expanding stent capable of self-expanding, a self-expanding filter, etc.) implanted in a blood vessel V. In some embodiments, stent 2 includes a self-expanding nitinol stent. Stent 2 includes a tube having an inner surface 3 defining a central lumen 5. Stent 2 is placed at a treatment site in a blood vessel V of an associated patient.
[0031] The delivery of the stent 2 into the blood vessel V can be achieved, for example, by using a catheter or other intravascular device (not shown), which is inserted into the blood vessel via an incision and moved to the treatment site where the stent 2 is deployed. Various known stent delivery instrument systems can be used for this purpose. After the stent 2 is deployed into the blood vessel V, the intravascular device is withdrawn, leaving the deployed stent in place. In the case of a self-expanding (e.g., nitinol) stent, stent delivery usually requires the stent to be compressed into a groove at or near the tip of the intravascular device, and the stent is released by pushing the stent out of the groove using a suitable mechanism of the intravascular device (e.g., a wire or cable driven mechanism). In another method, the stent is deployed (which may or may not be self-expanding in this method), and an expandable balloon at or near the tip of the interventional device is positioned inside the deployed stent, and expands and expands and presses the stent into the wall of the blood vessel V. Typically, the stent 2 is a hollow tube, and is therefore used to increase the diameter of the blood vessel to relieve stenosis. However, it is also contemplated that the stent 2 may optionally include other features (not shown), such as a filter disposed within the central lumen 5 of the stent, or a one-way valve (e.g., a mitral valve or a tricuspid valve) disposed within the central lumen 5 of the stent to inhibit blood backflow. For example, such one-way valves are sometimes included in the veins of the legs to prevent blood from pooling in the feet or calves. The term stent as used herein is intended to encompass these variants.
[0032] like Figure 1 As shown, the self-expanding stent 2 can include one or more radiopaque markers 4 ( Figure 1 , two of which are shown, but any suitable number of markers can be used). The radiopaque marker 4 can take any form, such as a radiopaque coating applied to some or all of the wire or other material that makes up the stent 2, and / or a separate radiopaque marker element attached to the stent by metallurgical bonding, etc. Such a radiopaque marker 4 provides visibility of the stent 2 in a medical imaging modality (not shown), such as X-ray or computed tomography (CT), which can be used to provide visualization of the stent delivery process so that the stent 2 can be placed in the blood vessel V using, for example, the intravascular procedure just described.
[0033] At least one sensor 12 is attached to or embedded in the inner surface 3 of the stent 2. In one exemplary embodiment, the at least one sensor 12 includes a temperature sensor configured to measure the temperature of blood flowing through the central lumen 5 of the stent 2. In another exemplary embodiment, the at least one sensor 12 includes a fluid flow resistance sensor configured to measure the blood flow resistance of the stent 2 placed at the treatment site in the blood vessel V. In some embodiments, such a fluid flow resistance sensor may include two pressure sensors spaced along the axis of the central lumen 5 of the stent 2, measuring the measure of the fluid flow resistance as a measured pressure difference. In some examples, the at least one sensor 12 includes an active sensor including a storage capacitor configured to inductively power the at least one sensor 12. In other examples, the at least one sensor 12 includes a passive sensor powered by an externally applied magnetic field supplied by an associated magnetic source 6. In another example, instead of a radiopaque marker 4, the at least one sensor 12 can be coated with a radiopaque coating.
[0034] Figure 1 Also shown is an electronic processing device 18, such as a workstation computer, or more generally, a computer. The electronic processing device 18 may also include one or more server computers (e.g., interconnected to form a server cluster, cloud computing resources, etc.) to perform more complex computing tasks. The electronic processing device 18 includes typical components, such as an electronic processor 20 (e.g., a microprocessor), at least one user input device 22 (e.g., a mouse, keyboard, trackball, etc.), and a display device 24 (e.g., an LCD display, a plasma display, a cathode ray tube display, etc.). In some embodiments, the display device 24 can be a separate component from the electronic processing device 18, or can include two or more display devices.
[0035] The electronic processor 20 is operatively connected to one or more non-transient storage media 26. As non-limiting illustrative examples, the non-transient storage media 26 may include one or more of the following: a disk, RAID or other magnetic storage medium; a solid-state drive, a flash drive, an electrically erasable read-only memory (EEROM) or other electronic memory; an optical disk or other optical storage device; various combinations thereof, etc.; and may be, for example, a network storage device, an internal hard drive of the electronic processing device 18, various combinations thereof, etc. It should be understood that any reference to one or more non-transient media 26 herein should be broadly interpreted to cover a single medium or multiple media of the same or different types. Similarly, the electronic processor 20 may be implemented as a single electronic processor or two or more electronic processors. The non-transient storage medium 26 stores instructions that can be executed by at least one electronic processor 20. These instructions include instructions to generate a visualization of a graphical user interface (GUI) 28 for display on a display device 24.
[0036] The electronic processing device 18 is programmed to determine whether the blood flow resistance measured by the at least one sensor 12 is below a predetermined fluid flow resistance threshold (i.e., stored in the non-transitory storage medium 26) based on the measurement results obtained from the at least one sensor 12. An indication 29 that the blood flow resistance is below the predetermined fluid flow resistance threshold can be output on the display device 24.
[0037] Figure 1 Two sensors 12 are shown, but any suitable number of sensors 12 may be implemented. In some embodiments, the sensor(s) 12 include one or more pressure sensors 12 configured to measure the blood flow resistance caused by the stent 2 based on at least one pressure measurement collected by the pressure sensor(s) 12. For example, the sensor(s) 12 may include a first pressure sensor 12 and a second pressure sensor 12 disposed at spaced apart positions along the central axis of the central lumen 5. Such a spaced apart arrangement enables the blood flow resistance to be measured as the pressure difference between the readings of the two pressure sensors 12. As previously described, the blood flow resistance is not necessarily provided in standard flow resistance units, but is a quantitative measure of the blood flow resistance.
[0038] In another example, if Figure 2As shown, each sensor 12 includes a first permanent magnet and a second permanent magnet 14. In one example, the first permanent magnet and the second permanent magnet 14 can be connected by a coupler 16. By changing the distance between the two (for example, through a pressure-sensitive membrane), pressure and / or temperature can be measured. In another example, the first permanent magnet and the second permanent magnet 14 are positioned at opposite ends of the bracket 2. One of the first permanent magnet and the second permanent magnet 14 is fixed to the bracket 2, and the other of the first permanent magnet and the second permanent magnet 14 is configured to oscillate relative to the fixed magnet.
[0039] By using an externally applied magnetic field to induce the resonant rotational oscillation of at least one of the permanent magnets, it is possible to obtain the measurement result of the support placed at the treatment site from at least one sensor element. Some suitable sensors of this passive dual magnet type are described in the U.S. patent US2021 / 0244305A1 of Gleich et al., which are incorporated herein by reference in their entirety. In a design of this type, each sensor 12 includes two permanent magnets 14 connected by an elastic coupler 16 positioned inside a container (not shown), which is fastened to (e.g., embedded in) the inner surface 3 of the support 2. One magnet is held in a fixed position, while the other magnet oscillates freely as the rotation moves. (In another embodiment, both magnets can oscillate freely). The oscillation occurs at a resonant frequency, which is a function of the distance between the magnets 14, which can be changed according to the pressure or temperature measured by the sensor 12. The oscillation resonant frequency can be remotely sensed by measuring the magnetic field generated by the magnetic source 6. The free oscillation of the magnet 14 changes the magnetic field. Since the magnetic source 6 can be positioned outside the patient's body (typically placed near or on the patient's skin near the interior location of the support 2), this measurement is completely non-invasive.
[0040] In another example, if Figure 3As shown, the sensor(s) 12 comprises a first sensor element 30 of a dual magnet type comprising a first magnet and a second magnet 32 connected by an elastic coupler 34, which is attached to or embedded in a first position of the inner surface 3 of the stent 2. A second sensor element 36 of a dual magnet type comprises a first permanent magnet and a second permanent magnet 38 connected by an elastic coupler 40, which is attached to or embedded in a second position of the inner surface 3 of the stent 2. The second position is spaced from the first position along the central axis of the central lumen 5 of the stent 2. The pressure difference between the readings of the two sensors 30 and 36 is used as a measure of the resistance to fluid flow, as follows: restenosis in the stent 2 is expected to cause an increase in flow resistance - therefore, an increase in the measured pressure difference over time is correlated with an increase in restenosis at the stent 2. In this method, in order to enable independent reading of the two pressure sensors 30 and 36, the two pressure sensors can optionally be designed to oscillate at different resonant frequencies. This can be achieved, for example, by making the mass and / or the magnetization of the elastic coupling 16 and / or the two permanent magnets 14 different from those of the two pressure sensors 30 and 36 .
[0041] At each visit, a sweep of the frequency of the magnetic field generated by the magnetic source 6 is applied to identify the resonant frequency of each of the two dual-magnet pressure sensors 12. In order to assess restenosis over time, in a suitable workflow, such measurements are performed at successive time intervals (e.g., at successive doctor's office visits). The pressure difference (here, a fluid flow metric) is measured at each such visit, thereby generating a curve of fluid flow resistance relative to time for days, weeks, months, or years. Based on this curve, the doctor can assess the degree of restenosis. This assessment can be based on a threshold, or can be based on the rate of increase of flow resistance over time (i.e., the slope of the curve of fluid flow resistance relative to time). Optionally, clinical trials can be used to calibrate the relationship between the degree of restenosis and the change in fluid flow resistance (or resistance slope) over time measured using sensors 30, 36. In another approach, an in vitro bench test can be performed (e.g., using a porcine blood vessel in which an example of a stent 2 is implanted and a mechanical pump that provides saline solution flow simulating blood flow) to calibrate this relationship.
[0042] These are merely examples and should not be construed as limiting. These examples can also use temperature readings measured by sensor 12 instead of pressure readings.
[0043] As described above, at least one electronic processor 20 is configured to perform a vascular treatment method or process 100. Non-transitory storage medium 26 stores instructions that can be read and executed by at least one electronic processor 20 to perform the disclosed operations, including performing the vascular treatment method or process 100. In some examples, method 100 can be performed at least in part through cloud processing.
[0044] refer to Figure 4 And continue to refer to Figure 1-3 , an illustrative embodiment of a vascular treatment method 100 is schematically shown as a flow chart. To begin the method 100 , a stent 2 is deployed into the blood vessel V via a treatment device 10 at a treatment location in the blood vessel V of a patient.
[0045] At operation 102, sensor(s) 12 measure blood flow resistance measurements caused by a stent (2) installed in a blood vessel V, and the blood flow resistance measurements are received by an electronic processing device 18. At operation 104, the electronic processing device 18 determines whether the blood flow resistance is below a predetermined fluid flow resistance threshold. At operation 106, an indication 29 that the blood flow resistance is below the predetermined fluid flow resistance threshold is output on a display device 24. As previously described, other metrics may be used (e.g., the slope or other characteristics of a curve of blood flow resistance versus time measured in successive physician's office visits).
[0046] The present disclosure has been described with reference to the preferred embodiments. Modifications and alterations may occur to others after reading and understanding the preceding detailed description. It is intended that the exemplary embodiments be interpreted as including all such modifications and alterations as long as they fall within the scope of the appended claims or their equivalents.
Claims
1. A vascular treatment device (10), comprising: a stent (2) comprising a tube having an inner surface (3) defining a central lumen (5), the stent being configured to be placed at a treatment site in a blood vessel of an associated patient; as well as At least one sensor (12) is attached to or embedded in the inner surface of the support.
2. The vascular treatment device (10) according to claim 1, wherein: The at least one sensor (12) includes a fluid flow resistance sensor configured to measure blood flow resistance at the treatment site in the blood vessel.
3. The vascular treatment device (10) of claim 2, further comprising an electronic processing device (18) configured to: determining whether the blood flow resistance is below a predetermined fluid flow resistance threshold; and An indication (29) that the blood flow resistance is below the predetermined fluid flow resistance threshold is output on a display device (24).
4. The vascular treatment device (10) according to any one of claims 1 to 3, wherein: The at least one sensor (12) comprises: One or more pressure sensors are configured to measure the blood flow resistance caused by the stent (2) based on at least one pressure measurement result collected by the one or more pressure sensors.
5. The vascular treatment device (10) according to claim 1, wherein: The at least one sensor (12) comprises: A first pressure sensor and a second pressure sensor are disposed at spaced-apart positions along the central axis of the central lumen (5).
6. The vascular treatment device (10) according to any one of claims 1 to 5, wherein: The at least one sensor (12) comprises at least one sensor element, the at least one sensor element comprising a first permanent magnet and a second permanent magnet (14) connected by an elastic coupler (16); Therein, by inducing a resonant rotational oscillation of at least one of the permanent magnets using an externally applied magnetic field, a measurement result of the support (2) placed at the treatment site can be obtained from the at least one sensor element.
7. The vascular treatment device (10) according to claim 6, wherein: The at least one sensor element comprising a first permanent magnet and a second permanent magnet (14) connected by an elastic coupler (16) comprises: a first sensor element (30) comprising a first permanent magnet and a second permanent magnet (32) connected by an elastic coupler (34) attached to or embedded in a first position of the inner surface (3) of the support (2); and a second sensor element (36) comprising a first permanent magnet and a second permanent magnet (38) connected by an elastic coupler (40) attached to or embedded in a second location of the inner surface of the bracket; Wherein, the second position is spaced apart from the first position along the central axis of the central lumen (5) of the stent.
8. The vascular treatment device (10) according to any one of claims 1 to 7, wherein: The at least one sensor (12) comprises a passive sensor powered by an externally applied magnetic field supplied by an associated magnetic source (6).
9. The vascular treatment device (10) according to any one of claims 1 to 7, wherein: The at least one sensor (12) comprises an active sensor including a storage capacitor configured to inductively power the at least one sensor.
10. The vascular treatment device (10) according to claim 1, wherein: The at least one sensor (12) comprises a temperature sensor configured to measure the temperature of blood flowing through the central lumen (5) of the stent (2).
11. The vascular treatment device (10) according to claim 10, wherein: The at least one sensor (12) comprises: A first temperature sensor and a second temperature sensor are disposed at spaced-apart locations along a central axis of the central lumen (5).
12. The vascular treatment device (10) according to any one of claims 1 to 11, wherein: The stent (2) comprises a self-expanding nitinol stent.
13. A vascular treatment device (10), comprising: a stent (2) comprising a tube having an inner surface (3) defining a central lumen (5), the stent being configured to be placed at a treatment site in a blood vessel of an associated patient; as well as At least one pressure sensor (12) is attached to or embedded in the inner surface of the support, the at least one pressure sensor being configured to acquire at least one pressure measurement including blood flow resistance.
14. The vascular treatment device (10) of claim 13, further comprising an electronic processing device (18) configured to: determining whether the blood flow resistance is below a predetermined fluid flow resistance threshold; and An indication (29) that the blood flow resistance is below the predetermined fluid flow resistance threshold is output on a display device (24).
15. The vascular treatment device (10) according to any one of claims 13 and 14, wherein: The at least one pressure sensor (12) comprises: A first pressure sensor and a second pressure sensor are disposed at spaced-apart positions along the central axis of the central lumen (5).
16. The vascular treatment device (10) according to any one of claims 13 to 15, wherein: The at least one sensor (12) comprises at least one pressure sensor element, the at least one pressure sensor element comprising a first permanent magnet and a second permanent magnet (14) connected by an elastic coupler (16); Therein, by inducing a resonant rotational oscillation of at least one of the permanent magnets using an externally applied magnetic field, a measurement result of the support (2) placed at the treatment site can be obtained from the at least one pressure sensor element.
17. The vascular treatment device (10) according to claim 16, wherein: The at least one pressure sensor element comprising a first permanent magnet and a second permanent magnet (14) connected by an elastic coupler (16) comprises: a first pressure sensor element (30) comprising a first permanent magnet and a second permanent magnet (32) connected by an elastic coupler (34) attached to or embedded in a first location of the inner surface (3) of the support (2); and a second pressure sensor element (36) comprising a first permanent magnet and a second permanent magnet (38) connected by an elastic coupler (40) attached to or embedded in a second location of the inner surface of the bracket; Wherein, the second position is spaced apart from the first position along the central axis of the central lumen (5) of the stent.
18. The vascular treatment device (10) according to any one of claims 6 and 7, wherein: The at least one pressure sensor (12) comprises one of the following: a passive sensor powered by an externally applied magnetic field supplied by an associated magnetic source (6); An active sensor includes a storage capacitor configured to inductively power the at least one sensor.
19. The vascular treatment device (10) according to any one of claims 13 to 18, wherein: The stent (2) comprises one or more radiopaque markers (4); wherein the electronic processing device (18) is programmed to perform image analysis based on changes in configuration of the one or more radiopaque markers in successive images of a time series of images of the stent, the successive images of the time series of images of the stent being acquired during a placement procedure of the stent (2) within the blood vessel.
20. A vascular treatment method (100), comprising: receiving a measurement of blood flow resistance caused by a stent (2) installed in a blood vessel, the blood flow resistance measurement being based on at least one measurement performed using one or more sensors (12); repeating the blood flow resistance measurement in successive time periods to generate a blood flow resistance versus time curve; assessing restenosis at the stent based on a curve of the blood flow resistance versus time; and An indication (29) of the assessment of restenosis is output on a display device (24).
